AIT Therapeutics (OTCMKTS:AITB) has been assigned a $16.00 target price by stock analysts at Roth Capital in a note issued to investors on Saturday. The brokerage presently has a “buy” rating on the stock. Roth Capital’s price objective indicates a potential upside of 185.71% from the company’s current price.
Several other analysts also recently weighed in on the stock. Laidlaw began coverage on shares of AIT Therapeutics in a report on Thursday, August 24th. They issued a “buy” rating and a $16.00 target price on the stock. Ladenburg Thalmann Financial Services began coverage on shares of AIT Therapeutics in a report on Monday, August 7th. They issued a “buy” rating on the stock.
Shares of AIT Therapeutics (OTCMKTS AITB) traded down $0.50 during trading hours on Friday, hitting $5.60. 7,038 shares of the stock traded hands, compared to its average volume of 15,624. AIT Therapeutics has a 1-year low of $4.32 and a 1-year high of $10.00.
About AIT Therapeutics
AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.
Receive News & Ratings for AIT Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.